The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding
Open accessAbstract
Background— A number of distinct stress signaling pathways in myocardium cause cardiac hypertrophy and heart failure. Class II histone deacetylases (HDACs) antagonize several stress-induced pathways and hypertrophy. However, cardiac hypertrophy induced by transgenic overexpression of the homeodomain only protein, HOP, can be prevented by the nonspecific HDAC inhibitors trichostatin A and valproic acid, suggesting that alternate targets that oppose class II HDAC function might exist in myocardium. We tested the effects of several HDAC inhibitors, including a class I HDAC-selective inhibitor, SK-7041, on cardiac hypertrophy induced by angiotensin II (Ang II) treatment or aortic banding (AB). Methods and Results— Cardiac hypertrophy was induced by chronic infusion of Ang II or by AB in mice or rats and evaluated by determining the ratio of heart weight to body weight or to tibia length, cross-sectional area, or echocardiogram. Cardiac hypertrophy induced by Ang II or AB for 2 weeks was significantly reduced by simultaneous administration of trichostatin A, valproic acid, or SK-7041. Echocardiogram revealed that exaggerated left ventricular systolic dimensions were relieved by HDAC inhibitors. HDAC inhibitors partially reversed preestablished cardiac hypertrophy and improved survival of AB mice. The expressions of atrial natriuretic factor, α-tubulin, β-myosin heavy chain, and interstitial fibrosis were reduced by HDAC inhibition. Conclusions— These results suggest that the predominant effect of HDAC inhibition, mainly mediated by class I HDACs, is to prevent cardiac hypertrophy in response to a broad range of agonist and stretch stimuli.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
THE CELLULAR AND MOLECULAR RESPONSE OF CARDIAC MYOCYTES TO MECHANICAL STRESS
Sadoshima, J., & Izumo, S. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.551 · Cited by 864
Post-translational modifications regulate microtubule function
Westermann, S., & Weber, K. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1260 · Cited by 717
Gui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Histone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Izumo, S., Lompré, A. M., Matsuoka, R., Koren, G., Schwartz, K., Nadal-Ginard, B., & Mahdavi, V (1987) · Journal of Clinical Investigation · doi:10.1172/jci112908 · Cited by 447
Signaling Network Model of Chromatin
Schreiber, S. L., & Bernstein, B. E. (2002) · Cell · doi:10.1016/s0092-8674(02)01196-0 · Cited by 393
Cited by
Regulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage
Bartolomaeus, H., Balogh, A., Yakoub, M., Homann, S., Markó, L., Höges, S., Tsvetkov, D., Krannich, A., Wundersitz, S., Avery, E. G., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036652 · Cited by 815
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 712
Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708
Kim, S., Goel, R., Kumar, A., Qi, Y., Lobaton, G., Hosaka, K., Mohammed, M., Handberg, E. M., Richards, E. M., Pepine, C. J., et al. (2018) · Clinical Science · doi:10.1042/cs20180087 · Cited by 542
Chromatin regulation by Brg1 underlies heart muscle development and disease
Hang, C. T., Yang, J., Han, P., Cheng, H.-L., Shang, C., Ashley, E., Zhou, B., & Chang, C.-P. (2010) · Nature · doi:10.1038/nature09130 · Cited by 470
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity
Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., Noppinger, P. R., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 468
Self-citationHDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
Signaling effectors underlying pathologic growth and remodeling of the heart
van Berlo, J. H., Maillet, M., & Molkentin, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62839 · Cited by 445
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405
Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy
Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B. A., Olson, E. N., & Hill, J. A. (2006) · Circulation · doi:10.1161/circulationaha.106.625467 · Cited by 377
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice
Montgomery, R. L., Potthoff, M. J., Haberland, M., Qi, X., Matsuzaki, S., Humphries, K. M., Richardson, J. A., Bassel-Duby, R., & Olson, E. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35847 · Cited by 362
Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials
Shi, Y., Zhang, H., Huang, S., Yin, L., Wang, F., Luo, P., & Huang, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01055-2 · Cited by 362
Noh, H., Oh, E. Y., Seo, J. Y., Yu, M. R., Kim, Y. O., Ha, H., & Lee, H. B. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00086.2009 · Cited by 254
Therapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
Epigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163
Metadata
- Authors
- Kee, H. J., Sohn, I. S., Nam, K. I., Park, J. E., Qian, Y. R., Yin, Z., Ahn, Y., Jeong, M. H., Bang, Y.-J., Kim, N., Kim, J.-K., Kim, K. K., Epstein, J. A., & Kook, H.
- Venue
- Circulation
- Published
- 2006-01-03
- Volume
- 113
- Issue
- 1
- Pages
- 51-59
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2142491779
- Cited by
- 368
- References
- 32
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.